BCL2 and melanoma: While the effects on ROS in response to the inhibitor combinations used here had not previously been investigated, some increase in ROS levels has been reported in melanoma cells in response to the Mcl-1/Bcl-xL/Bcl-2-selective BH3 mimetic TW-37 [81].